Assembly Biosciences

132 articles about Assembly Biosciences

• Assembly Biosciences Regains Worldwide Rights to Microbiome Gastrointestinal Development Programs

  6/18/2020

  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that the Company will regain worldwide rights to all microbiome gastrointestinal programs licensed under its collaboration agreement with AbbVie

• 

  How COVID-19 is Affecting Clinical Trials and Drug Supplies from Biotech Bay Companies

  6/5/2020

  Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.

• Assembly Biosciences Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

  6/1/2020

  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced grants of inducement awards to both its Chief Scientific Officer, Virology, William Delaney, Ph.D., and eight new employees on May 27, 2020 and June 1, 2020, respectively.

• Assembly Biosciences Announces Management Transition

  5/27/2020

  Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, announced the appointment of William Delaney, PhD as Chief Scientific Officer, Virology, replacing Richard Colonno, PhD, who will retire and transition from this role on June 1, 2020.

• Assembly Biosciences to Present During the Jefferies 2020 Virtual Healthcare Conference

  5/26/2020

  Assembly Biosciences, Inc. announced that John McHutchison, AO, MD, Chief Executive Officer and President, will present during the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 1:30 pm ET.

• Assembly Biosciences Announces Move to Virtual-Only Annual Meeting of Stockholders on June 11, 2020

  5/19/2020

  Assembly Biosciences, Inc. (Nasdaq: ASMB) today announced that it will hold its 2020 Annual Meeting of Stockholders (Annual Meeting) solely by means of remote communication (i.e., a virtual-only stockholder meeting).

• Assembly Biosciences Reports Updates on Corporate Progress and First Quarter 2020 Financial Results

  5/7/2020

  Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, reported financial results for the first quarter ended March 31, 2020 and provided an update on recent corporate progress.

• Preclinical Data from Assembly Biosciences’ Microbiome Program in Ulcerative Colitis Featured in DDW 2020 Virtual Meeting Portal and Upcoming Journal Supplements

  5/4/2020

  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that the abstract accepted as an ePoster presentation at Digestive Disease Week (DDW) 2020 Virtual Meeting may now be viewed at the online meeting portal . The ePoster includes preclinical data from the Company’s microbio

• Assembly Biosciences Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - May 01, 2020

  5/1/2020

  Assembly Biosciences, Inc. announced grants of stock options to two new employees to purchase an aggregate of 7,000 shares of Assembly’s common stock with an exercise price of $17.01 per share, the closing price on May 1, 2020.

• Assembly Biosciences to Host Conference Call and Webcast to Review HBV Portfolio Progress

  4/30/2020

  Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, announced plans to host a conference call and live audio webcast on Thursday, May 7, 2020 at 1:30 pm PT / 4:30 pm ET.

• Research by Assembly Biosciences and Academic Collaborators Published in Hepatology Indicates cccDNA Turnover Time May Enable Hepatitis B Cures Following Finite Therapy

  4/6/2020

  Data demonstrate turnover is faster than previously described for cccDNA, a necessary component required for the establishment and persistence of HBV infection

• Assembly Biosciences Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - March 31, 2020

  3/31/2020

  Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, announced a grant of inducement awards to its Chief Legal and Business Officer, Jason A. Okazaki on March 26, 2020.

• Assembly Biosciences Appoints Jason Okazaki as Chief Legal and Business Officer

  3/30/2020

  Assembly Biosciences, Inc. , today announced the appointment of Jason Okazaki as Chief Legal and Business Officer. Mr. Okazaki has 20 years of legal and biotechnology industry experience, both as internal counsel and with a leading law firm. “Jason brings extensive

• Assembly Biosciences Reports Fourth Quarter and Year End 2019 Financial Results

  3/4/2020

  Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today reported financial results and recent highlights for the fourth quarter and year ended December 31, 2019. 

• Assembly Biosciences to Present at the 9th Annual SVB Leerink Global Healthcare Conference

  2/19/2020

  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that John McHutchison, AO, MD, Chief Executive Officer and President will present at the 9th Annual SVB Leerink Global Healthcare Conference

• Assembly Biosciences Announces the Closing of its Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

  12/16/2019

  Assembly intends to use the net proceeds from the sale of the common stock to fund clinical trials, nonclinical studies, research and development and for general corporate purposes. 

• Assembly Biosciences Announces Pricing of $125 Million Public Offering

  12/12/2019

  Assembly Biosciences, Inc. (Nasdaq: ASMB) (“Assembly”), today announced the pricing of an underwritten public offering of 5,151,515 shares of its common stock to the public at $16.50 per share

• Assembly Biosciences Announces Proposed Public Offering of Common Stock - Dec. 11, 2019

  12/11/2019

  Assembly Biosciences, Inc. announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.

• Assembly Biosciences Announces Plenary Lecture at HEP DART 2019

  12/6/2019

  Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced that Richard Colonno, PhD, Executive Vice President and Chief Scientific Officer Virology, will present a Plenary Lecture, “Eliminating Residual HBV Replication – A Critical Gateway to Cure” at the HEP DART Meeting on Tuesday, Dec 10, 2019 at 5:30pm HST in Kauai, HI.

• 

  Inflammatory Bowel Disease Insight Report: Current Therapies, Drug Pipeline and Outlook

  11/19/2019

  Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.